according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Moxifloxacin Solid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.12
 28.09.2024
 1732314-00016
 Date of first issue: 05.06.2017

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Moxifloxacin Solid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Kilsheelan

Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person

responsible for the SDS

EHSDATASTEWARD@msd.com

# 1.4 Emergency telephone number

+1-908-423-6000

# **SECTION 2: Hazards identification**

## 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Acute toxicity, Category 4 H302: Harmful if swallowed.

Eye irritation, Category 2 H319: Causes serious eye irritation.

Reproductive toxicity, Category 2 H361d: Suspected of damaging the unborn child. Specific target organ toxicity - repeated H373: May cause damage to organs through pro-

exposure, Category 2 longed or repeated exposure.

## 2.2 Label elements

## Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

**(!**)

Signal word : Warning

Hazard statements : H302 Harmful if swallowed.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Moxifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 1732314-00016 Date of first issue: 05.06.2017

H319 Causes serious eye irritation.

H361d Suspected of damaging the unborn child.

H373 May cause damage to organs through prolonged or

repeated exposure.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON

CENTER/ doctor if you feel unwell. Rinse mouth.

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P337 + P313 If eye irritation persists: Get medical advice/

attention.

Hazardous components which must be listed on the label:

Moxifloxacin HCL

## 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

## Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Moxifloxacin HCL	186826-86-8	Acute Tox. 4; H302 Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 2; H373 (Liver)	>= 40 - <= 70

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Moxifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 1732314-00016 Date of first issue: 05.06.2017

For explanation of abbreviations see section 16.

#### **SECTION 4: First aid measures**

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Harmful if swallowed.

Causes serious eye irritation.

Suspected of damaging the unborn child.

May cause damage to organs through prolonged or repeated

exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

# **SECTION 5: Firefighting measures**

## 5.1 Extinguishing media

Suitable extinguishing media : Water spray

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 1732314-00016 Date of first issue: 05.06.2017 2.12

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

## **SECTION 6: Accidental release measures**

## 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

**Environmental precautions** Avoid release to the environment.

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable con-Methods for cleaning up

tainer for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Moxifloxacin Solid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.12
 28.09.2024
 1732314-00016
 Date of first issue: 05.06.2017

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

**SECTION 7: Handling and storage** 

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust, fume, gas, mist, vapours or spray.

Do not swallow. Do not get in eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Store in

accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

# **SECTION 8: Exposure controls/personal protection**

## 8.1 Control parameters

## Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Moxifloxacin HCL	186826-86- 8	TWA	1000 μg/m3 (OEB 1)	Internal

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Moxifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.12 28.09.2024 1732314-00016 Date of first issue: 05.06.2017

#### 8.2 Exposure controls

#### **Engineering measures**

Use feasible engineering controls to minimize exposure to compound.

All engineering controls should be implemented by facility design and operated in accordance

with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Skin and body protection

: Work uniform or laboratory coat.

Respiratory protection

If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Equipment should conform to NS EN 143

Filter type : Particulates type (P)

## **SECTION 9: Physical and chemical properties**

## 9.1 Information on basic physical and chemical properties

Physical state : solid

Colour : pink

Odour : odourless

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : Not applicable

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Moxifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.12 28.09.2024 1732314-00016 Date of first issue: 05.06.2017

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : Not applicable

## **SECTION 10: Stability and reactivity**

# 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

## 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Moxifloxacin Solid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.12
 28.09.2024
 1732314-00016
 Date of first issue: 05.06.2017

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

**SECTION 11: Toxicological information** 

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Skin contact exposure Ingestion

Eye contact

**Acute toxicity** 

Harmful if swallowed.

**Product:** 

Acute oral toxicity : Acute toxicity estimate: 1.886 mg/kg

Method: Calculation method

**Components:** 

**Moxifloxacin HCL:** 

Acute oral toxicity : LD50 (Rat): 1.320 mg/kg

LD50 (Mouse): > 435 mg/kg

LD50 (Monkey): 1.500 mg/kg

Skin corrosion/irritation

Not classified based on available information.

**Components:** 

Moxifloxacin HCL:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

**Components:** 

**Moxifloxacin HCL:** 

Species : Rabbit

Result : Moderate eye irritation

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Moxifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.12 28.09.2024 1732314-00016 Date of first issue: 05.06.2017

#### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

## Respiratory sensitisation

Not classified based on available information.

## Germ cell mutagenicity

Not classified based on available information.

#### **Components:**

#### **Moxifloxacin HCL:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: positive

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: in vitro micronucleus test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay)
Application Route: Oral

Result: negative

#### Carcinogenicity

Not classified based on available information.

#### Reproductive toxicity

Suspected of damaging the unborn child.

## **Components:**

#### **Moxifloxacin HCL:**

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: LOAEL: 500 mg/kg body weight

Result: Effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Monkey Application Route: Oral

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: negative

Test Type: Embryo-foetal development

Species: Rabbit

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Moxifloxacin Solid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.12
 28.09.2024
 1732314-00016
 Date of first issue: 05.06.2017

Application Route: Intravenous injection

Developmental Toxicity: LOAEL: 20 mg/kg body weight

Symptoms: Skeletal malformations

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

## STOT - single exposure

Not classified based on available information.

## STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

## **Components:**

## **Moxifloxacin HCL:**

Target Organs : Liver

Assessment : May cause damage to organs through prolonged or repeated

exposure.

#### Repeated dose toxicity

# **Components:**

#### **Moxifloxacin HCL:**

Species : Rat
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 4 Weeks

Species : Rat

NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Liver

Symptoms : Liver disorders

Species : Rat

NOAEL : 20 mg/kg

Application Route : Oral

Exposure time : 6 Months

Target Organs : Liver

Symptoms : Liver disorders

Species : Monkey
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 4 Weeks

Symptoms : No adverse effects

Species : Monkey
NOAEL : 15 mg/kg
Application Route : Oral

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Moxifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 1732314-00016 Date of first issue: 05.06.2017

Exposure time : 13 Weeks

Target Organs : Gastrointestinal tract

Symptoms : Vomiting

Species : Monkey
Application Route : Oral
Exposure time : 26 Weeks
Target Organs : Liver

Symptoms : Liver disorders

## **Aspiration toxicity**

Not classified based on available information.

#### 11.2 Information on other hazards

#### **Endocrine disrupting properties**

#### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### **Experience with human exposure**

#### Components:

## **Moxifloxacin HCL:**

Ingestion : Symptoms: Nausea, Abdominal pain, Headache, Dizziness,

central nervous system effects, joint pain

## **SECTION 12: Ecological information**

#### 12.1 Toxicity

No data available

## 12.2 Persistence and degradability

No data available

## 12.3 Bioaccumulative potential

No data available

## 12.4 Mobility in soil

No data available

#### 12.5 Results of PBT and vPvB assessment

## **Product:**

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Moxifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 28.09.2024 1732314-00016 Date of first issue: 05.06.2017

## 12.6 Endocrine disrupting properties

#### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### 12.7 Other adverse effects

No data available

## **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

## **SECTION 14: Transport information**

#### 14.1 UN number or ID number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Moxifloxacin Solid Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
2.12	28.09.2024	1732314-00016	Date of first issue: 05.06.2017

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

#### 14.5 Environmental hazards

Not regulated as a dangerous good

## 14.6 Special precautions for user

Not applicable

## 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

# **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on : Not applicable

the market and use of certain dangerous substances,

mixtures and articles (Annex XVII)

REACH - Candidate List of Substances of Very High : Not applicable

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Regulation (EC) on substances that deplete the ozone : Not applicable

layer

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

Regulation (EU) No 649/2012 of the European Parlia: Not applicable

ment and the Council concerning the export and import

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

# Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Moxifloxacin Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 2.12 28.09.2024 1732314-00016 Date of first issue: 05.06.2017

working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

## 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

## **Full text of H-Statements**

H302 : Harmful if swallowed.

H319 : Causes serious eye irritation.

H361d : Suspected of damaging the unborn child.

H373 : May cause damage to organs through prolonged or repeated

exposure.

#### Full text of other abbreviations

Acute Tox. : Acute toxicity Eye Irrit. : Eye irritation

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization: IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Ef-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Moxifloxacin Solid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 2.12
 28.09.2024
 1732314-00016
 Date of first issue: 05.06.2017

fect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Sources of key data used to : compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agentus http://ocho.ourope.ou/

cy, http://echa.europa.eu/

#### Classification of the mixture:

## Classification procedure:

Acute Tox. 4 H302 Calculation method
Eye Irrit. 2 H319 Calculation method
Repr. 2 H361d Calculation method
STOT RE 2 H373 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN